1. Home
  2. Live Updates
  3. Roche holdings

Live Breaking News & Updates on Roche holdings

Stay informed with the latest breaking news from Roche holdings on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Roche holdings and stay connected to the pulse of your community

Why Roche Holdings Stock Popped Today

Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate.

Switzerland , United-states , Swiss , Americans , World-health-organization , Drug-administration , Roche-holdings , Eli-lilly , Breakthrough-device-designation , Motley-fool-stock-advisor , Stock-advisor

Why Roche Holdings Stock Popped Today | The Motley Fool

Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate.

Switzerland , United-states , Swiss , Americans , Roche-holdings , Drug-administration , World-health-organization , Eli-lilly , Breakthrough-device-designation ,

Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data - Alnylam Pharmaceuticals (NASDAQ:ALNY)

The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood pressure with standard-of-care antihypertensives.

William-blair , Roche-holdings , Alnylam-pharmaceuticals-inc ,

This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies

Monday, Roche Holdings AG RHHBY announced data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase 3 OUtMATCH study of Xolair…

United-states , American , Roche-holdings , American-academy , National-institutes-of-health , National-institutes , New-england-journal , News , Ggregator , Reaking-news , Uration

This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies - Novartis (NYSE:NVS)

Results from Roche's Phase 3 OUtMATCH study on Xolair for multi-food allergies. Published in NEJM, the study reveals increased tolerance in patients aged 1-55. FDA-approved expanded use for IgE-mediated food allergies.

United-states , American , American-academy-of-allergy , Roche-holdings-agrhhbyannounced , National-institutes-of-health , Roche-holdings , National-institutes , New-england-journal , Immunology-annual ,

Form PRE 14A Akili, Inc. For: Apr 17

Form PRE 14A Akili, Inc. For: Apr 17
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Arizona , United-states , California , District-of-columbia , Texas , California-academy-of-sciences , Boston , Massachusetts , Menlo-park , Paris , France-general- , France

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Anders-harfstrand , Lars-ekman , Larsg-ekman , Danielg-welch , Structure-therapeutics-inc , Gilead-sciences , Triangle-pharmaceuticals-inc , Nuvation-bio-inc , Novartis , Seagen-inc , Prothena-corporation , University-of-miami

Why Is Sarepta Therapeutics Stock Trading Higher Today? - Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024.

William-blair , Doug-ingram , Roche-holdings , Sarepta-therapeutics-inc , Biologics-license-application , Efficacy-supplement , Priority-review , Sarepta-therapeutics ,

Why Is Monte Rosa Therapeutics Stock Trading Higher Today? - Monte Rosa Therapeutics (NASDAQ:GLUE)

Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the company shows strong potential for value creation.

Monte-rosa , Roche-holdings , Monte-rosa-therapeutics-inc , Rosa-therapeutic , Monte-rosa-therapeutics ,

Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month Why Repare Therapeutics Stock Is Tumbling Today - Repare Therapeutics (NASDAQ:RPTX), Roche Holding (OTC:RHHBY)

Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved.

Pharma-inc , Roche-holdings , Repare-therapeutics ,